Indication
Dermatitis
46 clinical trials
57 products
1 drug
Clinical trial
A Phase Ib/II Study to Evaluate the Safety, Pharmacokinetic and Efficacy of Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) in Chinese Children and Adolescents (6 Years Old ≤ Age <18 Years Old) With Moderate to Severe Atopic DermatitisStatus: Not yet recruiting, Estimated PCD: 2024-08-01
Product
611Clinical trial
A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase II Clinical Trial, to Evaluate the Efficacy and Safety of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis.Status: Completed, Estimated PCD: 2023-07-10
Product
Matching placeboClinical trial
A Study Evaluated the Safety and Efficacy of BAT6026 in Patients With Moderate to Severe Atopic Dermatitis Phase I/II Clinical StudyStatus: Recruiting, Estimated PCD: 2025-02-01
Product
Sodium ChlorideClinical trial
A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of 611 (Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic DermatitisStatus: Recruiting, Estimated PCD: 2025-09-01
Product
BAT6026Product
ASN008Product
BMS-986326Clinical trial
A Phase 1b, Randomized, Double-blind, Placebo-controlled, Single Dose, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 at Two Dose Levels in Adult Participants With Atopic DermatitisStatus: Not yet recruiting, Estimated PCD: 2025-10-31
Product
CC-93538Clinical trial
A Phase 2, Multicenter, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects With Moderate to Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2022-07-20
Product
LY3844583Clinical trial
A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of LY3844583 in Healthy Participants, and Multiple-Dose Study of LY3844583 in Healthy Participants and Patients With Atopic DermatitisStatus: Completed, Estimated PCD: 2024-01-20
Product
PlaceboClinical trial
A Randomized, Double-Blind, Vehicle-Controlled, Phase 2 Trial to Evaluate the Anti-pruritic Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN008 in Adults With Mild to Moderate Atopic DermatitisStatus: Completed, Estimated PCD: 2023-11-27
Product
LY3471851Clinical trial
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic DermatitisStatus: Completed, Estimated PCD: 2022-06-24
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of a Single Intravenous Dose of GSK1070806 Administered to Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age InclusiveStatus: Completed, Estimated PCD: 2023-07-12
Product
GSK1070806Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic DermatitisStatus: Recruiting, Estimated PCD: 2025-01-01
Product
SCD-044Product
AbrocitinibProduct
NemolizumabClinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With NemolizumabStatus: Completed, Estimated PCD: 2023-07-07
Clinical trial
Cosmetic Dermatology and Inflammation of Chronic SkinStatus: Not yet recruiting, Estimated PCD: 2024-05-01
Product
LebrikizumabClinical trial
A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients With Moderate-To-Severe Atopic Dermatitis That Are Not Adequately Controlled With Cyclosporine or For Whom Cyclosporine is Not Medically Advisable.Status: Completed, Estimated PCD: 2023-01-30
Product
Matching PlaceboClinical trial
A 2-stage, Lead-in and Randomized, Phase 2, Open-label Study of Darolutamide Versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men With Hormone-Naïve Prostate CancerStatus: Recruiting, Estimated PCD: 2025-08-19
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Japanese Patients With Moderate-to-Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2022-07-31
Product
SCM-AGHClinical trial
A Randomized, Phase I/II Trial to Evaluate the Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2022-08-02
Product
611 150mgClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Patients With Moderate-to-Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2022-10-21
Clinical trial
Phase IIa, Multicentre, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Treatment With BI 655130 in Adult Patients With Moderate to Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2020-01-17
Product
BI 655130Clinical trial
Double-Blind, Placebo Controlled, Randomized, Multicenter, Parallel-Group Study to Compare the Efficacy and Safety of Advantan Cream Twice Weekly With Advabase Cream During a Maintenance Phase of 16 Weeks After Successful Treatment of Atopic Dermatitis With Advantan CreamStatus: Completed, Estimated PCD: 2006-05-01
Product
Methylprednisolone AceponateProduct
Fexofenadine HydrochlorideClinical trial
An Open Label, Single-Dose, Single-Treatment, Single-Period Safety and Bioavailability Study of Fexofenadine Hydrochloride Topical Lotion 1% in Healthy, Adult, Male Human SubjectsStatus: Completed, Estimated PCD: 2022-10-16
Product
Topical CorticosteroidProduct
KY1005Clinical trial
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2020-05-12
Clinical trial
A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients With Moderate to Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2022-08-22
Clinical trial
A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants With Moderate to Severe Atopic DermatitisStatus: Terminated, Estimated PCD: 2022-02-02
Product
DupilumabProduct
BermekimabProduct
BMS-986166Product
BranebrutinibClinical trial
Đánh giá hiệu quả điều trị viêm da dầu ở đầu của dầu gội Thái Dương 3 và Thái Dương 7 (A Randomized, Double Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy Shampoos TD03 and TD07 in Scalp Diseases)Status: Recruiting, Estimated PCD: 2022-12-01
Product
KetoconazoleClinical trial
A Phase 1, Randomized, Double-Blind, Vehicle-Controlled Ascending Doses Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASN008 Topical Gel in Healthy Volunteers and Subjects With Atopic DermatitisStatus: Completed, Estimated PCD: 2020-03-20
Product
BBI-5000Clinical trial
A Phase 2a, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Interventional Study to Assess the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Multiple IV Doses of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic DermatitisStatus: Terminated, Estimated PCD: 2022-03-09
Product
ASN008 TGProduct
Placebo TGClinical trial
Post Marketing Surveillance (PMS) Study for Cibinqo Tablet (Abrocitinib) in Patients With Moderate to Severe Atopic Dermatitis (AD) in KoreaStatus: Recruiting, Estimated PCD: 2027-11-22
Clinical trial
Efficacy and Safety of the Association of Dexamethasone 0.5 mg + Clemastine Fumarate 1 mg When Compared to Dexamethasone 0.5 mg in Patients With Allergic DermatitisStatus: Withdrawn, Estimated PCD: 2010-11-01
Product
DexamethasoneClinical trial
An Open-Label, Single-Dose, 4-Way Crossover, Bioavailability Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Food Effect of BBI-5000 Capsules in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2015-12-01
Product
AR100DP1Product
MK-6194Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-6194 in Participants With Moderate to Severe Atopic DermatitisStatus: Active (not recruiting), Estimated PCD: 2024-05-30
Product
ASN002Clinical trial
A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2017-11-05
Clinical trial
A Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Healthy Subjects, and Subjects With Mild to Moderate Atopic DermatitisStatus: Terminated, Estimated PCD: 2021-12-29
Clinical trial
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis PatientsStatus: Completed, Estimated PCD: 2022-12-19
Clinical trial
A Prospective Observational Study of Patients Receiving DUPIXENT® for Atopic DermatitisStatus: Active (not recruiting), Estimated PCD: 2027-03-30
Clinical trial
Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic DermatitisStatus: Recruiting, Estimated PCD: 2025-01-01
Product
CephalexinProduct
DoxycyclineClinical trial
A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus.Status: Completed, Estimated PCD: 2014-03-08
Product
DesloratadineClinical trial
Preventative Skin Care for Children Undergoing Targeted CNS Tumor TherapyStatus: Active (not recruiting), Estimated PCD: 2024-01-01
Product
SPF 30 or Higher SuncreenClinical trial
A Comparative Clinical Trial to Evaluate the Efficacy and Safety of Tacrolimus Versus Hydrocortisone in Treatment of Children With Atopic DermatitisStatus: Completed, Estimated PCD: 2022-11-20
Drug
VarlilumabProduct
HydrocortisoneClinical trial
Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone and Effects on Skin Circadian RhythmStatus: Withdrawn, Estimated PCD: 2024-06-01
Product
NaltrexoneClinical trial
Is 100% Pure Stabilized Whole Rice Bran (SWRB) Effective When Used as a Cleanser and an Emollient in Patients With Mild to Moderate Atopic Dermatitis?Status: Completed, Estimated PCD: 2021-04-20
Product
Stabilised Whole Rice BranClinical trial
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants With Moderate to Severe Atopic Dermatitis.Status: Not yet recruiting, Estimated PCD: 2029-11-07
Clinical trial
Multicenter Retrospective Cohort Study on Patients Receiving Extracorporeal Photopheresis for Immune-related Adverse Events After Checkpoint Inhibitor TreatmentStatus: Completed, Estimated PCD: 2022-12-30
Product
ECPClinical trial
Biologics and Blistering - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Through Suction BlisteringStatus: Recruiting, Estimated PCD: 2027-01-01
Product
Squaric Acid Dibutyl EsterProduct
AdalimumabProduct
UstekinumabProduct
GuselkumabProduct
CanakinumabProduct
SarilumabProduct
Triamcinolone AcetonideProduct
Betamethasone ValerateProduct
Fluticasone PropionateClinical trial
A Phase 2a, Multicenter, Randomized, Double-blind, 16-week Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate to Severe Atopic DermatitisStatus: Recruiting, Estimated PCD: 2025-02-01
Product
Camoteskimab